KRIBIOLISA™ Anti-Tremilimumab ELISA

Biotherapeutics can induce an immune response in the body, leading to the development of anti-drug antibodies (ADAs) which can potentially threaten patient safety. Assessment of ADAs, which may inhibit the biologic activity of the drug, form a fundamental part of immunogenicity testing.

Krishgen Anti-Drug Antibody kits are used for the quantification of antibodies specific to the drug, and can be used on both serum and plasma samples.

About the Anti-Tremilimumab ELISA kit:

• Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• Recovery rates are 80 - 120%
• Validated as per US FDA guidelines for Bioassays
• Optimized for matrix effects to ensure higher sensitivity
• Ship at 2-8 ^C for easy transport with lyophilized standards